Abstract:Background Upadacitinib (UPA) is the 1st oral, reversible, selective Janus kinase inhibitor that approved in China for moderately to severely active Crohn’s disease (CD) treatment. UPA demonstrated significantly greater efficacy compared with placebo (PBO) in phase 3 global multicenter, double-blind, PBO-controlled induction U-EXCEL and U-EXCEED studies. This analysis reports the efficacy and safety results on a sub-analysis of Chinese from the combined 2 induction studies. Methods Eligible patients with an average daily very soft/liquid stool frequency (SF) ≥4 and/or abdominal pain score (APS) ≥2, plus a Simple Endoscopic Score for CD (excluding the narrowing component) ≥6 (≥4 for isolated ileal disease) were randomized (2:1) to UPA 45 mg or PBO for 12 weeks. Patients receiving corticosteroid at baseline began a steroid taper at week 4 per protocol. This analysis included Chinese subjects from global population. The 2 induction studies were combined for each analysis set. Clinical remission per PROs was defined as average daily very soft or liquid SF ≤ 2.8 and average daily AP score ≤1.0 and both not greater than baseline. Endoscopic response was defined as decrease in SES-CD>50% from baseline (or for subjects with an SES-CD of 4 at baseline, at least a 2-point reduction), as scored by central reviewer. Results Of the 1021 patients enrolled in the 2 induction studies, 120 from China were included in the analysis. Baseline demographic and characteristics were mostly similar with a few exceptions. A significantly higher percentage of Chinese patients who received UPA 45mg QD than those received PBO had clinical remission per PROs at week 12 (70.9% vs 22.0%, p<0.0001). At week 4, clinical remission per PROs was achieved by a numerically greater proportion of patients receiving UPA (51.9%) than PBO (17.1%). At week 12, in patients taking corticosteroids for CD at baseline, a numerically greater proportion of patients receiving UPA (72%) discontinued corticosteroid use and achieved clinical remission per PROs than did patients receiving PBO (30%). A significantly higher percentage of Chinese patients who received UPA than those received PBO had endoscopic response at week 12 (64.6% vs 12.2%, p<0.0001). The rate of adverse events (AEs) in the UPA group was comparable to PBO group. There were no treatment-emergent deaths in either group. In the Chinese population, AEs of special interest occurred at similar rates between PBO and UPA group. No malignancies, adjudicated major cardiovascular events, or venous thromboembolic events were reported. Conclusion Similar to global population, Chinese patients treated with UPA 45mg achieved clinical and endoscopic outcomes at higher rates than did patients receiving PBO, with a tolerable safety profile.

P469 Effectiveness of Dose Optimisation by Pre-Genotyping NUDT 15 R139C on Reducing Thiopurine-Induced Leucopoenia in Chinese Patients with Crohn’s Disease: a Randomised Controlled Trial

Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease

P096 Combined Detection Variants of NUDT15 Could Highly Predict Thiopurine-Induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: a Multi-Center Analysis

Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: A Multicenter Analysis

OP11 Exploring the potential clinical utility of NUDT15 pharmacogenetic testing in clinical practice: a ‘focused reverse phenotyping’ study in the UK IBD Bioresource

The Predictive Role of MTHFR and ABCG2 Single Nucleotide Polymorphisms on the Outcome of Advanced Colorectal Cancer Treated with First-Line Chemotherapy

P440 Prevalence of NUDT15 polymorphisms and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease patients: A systematic review and meta-analysis

Inosine Triphosphate Pyrophosphatase and NUDT15 Are Good Predictors of Clinical Outcomes in Thiopurine-Treated Chinese Patients with Inflammatory Bowel Disease.

Early proactive monitoring of DNA-thioguanine in patients with Crohn’s disease predicts thiopurine-induced late leucopenia in NUDT15/TPMT normal metabolizers

Prevention of thiopurine-induced early leukopenia in a Korean pediatric patient with Crohn’s disease who turned out to possess homozygous mutations in NUDT15 R139C

Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.

NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients.

P574 Incidence and Indicators of Suboptimal Response to Tumour Necrosis Factor Antagonist Therapy in Chinese Patients with Inflammatory Bowel Disease: Results from the EXPLORE Study

Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease

XDH genotypes through gene-gene interactions with NUDT15 affect azathioprine-induced leukopenia in Chinese patients

Advances in genetic polymorphism of NUDT15 and leucopenia caused by thiopurines

NUDT15 R139C variation increases the risk of azathioprine-induced toxicity in Chinese subjects: Case report and literature review.

NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD

Indicators of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy in Patients from China with Inflammatory Bowel Disease: Results from the EXPLORE Study

NUDT15 R139C Variation Increases the Risk of Azathioprine-Induced Toxicity in Chinese Subjects

Efficacy of Induction Upadacitinib Therapy in Chinese Patients with Moderately to Severely Active Crohn's Disease